{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PDAC&page=5", "query": { "condition": "PDAC", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 157, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PDAC&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PDAC&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T21:17:42.341Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06704724", "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Pancreatic Ductal", "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "PF-07985045", "type": "DRUG" }, { "name": "Gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Nab-paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Fluorouracil", "type": "COMBINATION_PRODUCT" }, { "name": "Oxaliplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Leucovorin", "type": "COMBINATION_PRODUCT" }, { "name": "Bevacizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Sasanlimab", "type": "COMBINATION_PRODUCT" }, { "name": "pemetrexed", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "PF-07284892", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-12-10", "completion_date": "2026-05-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 12, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06704724" }, { "nct_id": "NCT05275075", "title": "Identify microRNAs in Cachexia in Pancreatic Carcinoma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Resectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Pancreatic cancer microRNA and messenger RNA expression.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-12-07", "completion_date": "2026-04-03", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05275075" }, { "nct_id": "NCT02583477", "title": "Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "MEDI4736 in combination with nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "MEDI4736 in combination with AZD5069", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 23, "start_date": "2016-03-25", "completion_date": "2018-07-09", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02583477" }, { "nct_id": "NCT06673017", "title": "PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "PTM-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PanTher Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-04-14", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 8, "location_summary": "Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673017" }, { "nct_id": "NCT05631574", "title": "Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Colorectal Cancer", "NSCLC", "PDAC", "CRC", "Relapsed Cancer", "Refractory Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer", "Stage III Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage III Colorectal Cancer", "Stage IV Colorectal Cancer", "Stage III NSCLC", "Stage IV NSCLC", "KRAS Mutation-Related Tumors" ], "interventions": [ { "name": "BMF-219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biomea Fusion Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2023-01-12", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 19, "location_summary": "Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05631574" }, { "nct_id": "NCT05634720", "title": "Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "HA Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2024-01-02", "completion_date": "2028-12-31", "has_results": true, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05634720" }, { "nct_id": "NCT06782932", "title": "Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "AGEN2373", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX", "type": "DRUG" }, { "name": "AGEN2373 (RP2D)", "type": "DRUG" }, { "name": "mKRASvax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2025-05-27", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06782932" }, { "nct_id": "NCT06157671", "title": "The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Adenocarcinoma", "Pancreatic Intraepithelial Neoplasia" ], "interventions": [], "intervention_types": [], "sponsor": "Adenocyte, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 1000, "start_date": "2024-01-31", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06157671" }, { "nct_id": "NCT06639724", "title": "Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-12-05", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06639724" }, { "nct_id": "NCT02672917", "title": "Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "MVT-5873", "type": "DRUG" }, { "name": "modified FOLFIRINOX (mFOLFIRINOX)", "type": "DRUG" }, { "name": "gemcitabine + nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech Research & Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2016-01", "completion_date": "2025-01-14", "has_results": false, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-19T21:17:42.341Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02672917" } ] }